Bioxel Pharma Inc.

Bioxel Pharma Inc.

March 14, 2007 08:30 ET

Bioxel Signs a Supply Agreement with a Medical Device Manufacturer

SAINTE-FOY, QUEBEC--(CCNMatthews - March 14, 2007) - Bioxel Pharma Inc. (TSX VENTURE: BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, today announced the completion of a paclitaxel supply agreement with a medical device company specialized in coated stents. The three-year renewable agreement provides for exclusive paclitaxel supplies to fulfill the client's needs from development through commercialization.

A stent is a little perforated tube that is inserted, most often, into coronary arteries in order to prevent decreases in vessel diameter. Adding paclitaxel at the surface of the stent further reduce the risk of occlusion of the vessel.

"We are very pleased to complete this agreement that allows Bioxel to gain a foothold in the coated stent market," said Pascal Delmas, President and Chief Executive Officer of Bioxel Pharma. "It is consistent with our strategy for global expansion and further reflects our objectives to broaden our customer base." Mr. Delmas added, "Clearly, Bioxel's secure supply chain, quality product and regulatory expertise provide value to our customers; allowing us to win business in competitive markets."

The client plans to secure marketing authorizations for its paclitaxel device in various territories, including Eastern Europe, Asia and South America. Paclitaxel deliveries are scheduled to start during the second quarter of 2007.

Bioxel manufactures and sells cGMP paclitaxel to specialty pharmaceutical companies, medical device manufacturers and generic formulators. The Corporation's dedicated cGMP paclitaxel facility has a 120-kilogram annual manufacturing capacity. It is located at an FDA inspected pharmaceutical manufacturing site. Bioxel's paclitaxel is registered with US, EU and Canadian regulatory authorities, allowing its use worldwide.


Bioxel Pharma Inc. is a biopharmaceutical company, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis, Alzheimer's disease and cardiovascular disease. The Corporation sells cGMP paclitaxel and develops a portfolio of other generic taxane APIs and taxane-based proprietary products for improved cancer therapy.

This announcement includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. These include risks and uncertainties that could affect Bioxel's products under development such as regulatory factors, technological developments and competitive factors. Achievement of the objectives set forth in this release is subject to these risks and uncertainties. The Corporation's results, or the measures it adopts, could differ materially from those indicated or underlying these statements, or could have an impact on the realization of financial projections.

Contact Information

  • Bioxel Pharma Inc.
    Pascal Delmas, Pharm.D, MBA
    President and Chief Executive Officer